BlackRock
RPRX icon

BlackRock’s Royalty Pharma RPRX Stock Holding History

BlackRock’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.56B Buy
27,832,977
+1,925,232
+7% +$100M 0.02% 531
2026
Q1 		$1.24B Sell
25,907,745
-280,947
-1% -$12.3M 0.02% 588
2025
Q4 		$1.01B Sell
26,188,692
-11,811
-0% -$450K 0.02% 685
2025
Q3 		$924M Buy
26,200,503
+771,647
+3% +$27.9M 0.02% 707
2025
Q2 		$916M Buy
25,428,856
+872,994
+4% +$28.9M 0.02% 683
2025
Q1 		$764M Sell
24,555,862
-890,658
-4% -$28.2M 0.02% 758
2024
Q4 		$649M Buy
25,446,520
+3,145,361
+14% +$83.4M 0.01% 912
2024
Q3 		$631M Sell
22,301,159
-716,402
-3% -$19.8M 0.01% 907
2024
Q2 		$607M Buy
23,017,561
+1,811,720
+9% +$50.2M 0.01% 867
2024
Q1 		$644M Sell
21,205,841
-253,621
-1% -$7.48M 0.02% 854
2023
Q4 		$603M Buy
21,459,462
+895,608
+4% +$24.6M 0.02% 866
2023
Q3 		$558M Sell
20,563,854
-177,665
-0.9% -$5.28M 0.02% 824
2023
Q2 		$638M Buy
20,741,519
+892,677
+4% +$30.2M 0.02% 780
2023
Q1 		$715M Buy
19,848,842
+435,591
+2% +$16.2M 0.02% 689
2022
Q4 		$767M Buy
19,413,251
+1,143,162
+6% +$47.7M 0.02% 631
2022
Q3 		$734M Sell
18,270,089
-127,551
-0.7% -$5.45M 0.03% 613
2022
Q2 		$773M Buy
18,397,640
+914,452
+5% +$37.5M 0.02% 611
2022
Q1 		$681M Buy
17,483,188
+767,864
+5% +$30.2M 0.02% 763
2021
Q4 		$666M Buy
16,715,324
+1,254,479
+8% +$48.7M 0.02% 817
2021
Q3 		$559M Buy
15,460,845
+5,173,204
+50% +$201M 0.02% 898
2021
Q2 		$422M Sell
10,287,641
-3,376,940
-25% -$144M 0.01% 1164
2021
Q1 		$596M Buy
13,664,581
+4,611,036
+51% +$219M 0.02% 860
2020
Q4 		$453M Buy
9,053,545
+5,321,913
+143% +$226M 0.01% 976
2020
Q3 		$157M Buy
3,731,632
+1,681,487
+82% +$72.1M 0.01% 1589
2020
Q2 		$99.5M Buy
+2,050,145
New +$101M ﹤0.01% 1848

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CIA
Caledonia Investments (Australia) Sydney NSW, Australia $2.93B AUM 37.21% 1-Year Est. Return

BlackRock's RPRX Position: Q2 2026 in Review

BlackRock increased its Royalty Pharma (RPRX) stake by 7.4% in Q2 2026, buying an estimated $100M and bringing the position to 27,832,977 shares worth $1.56B. The position accounts for 0.02% of the portfolio, ranked #531.

BlackRock first reported a position in RPRX in Q2 2020 and has held it in 25 quarters since. 643 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • BlackRock held 27,832,977 shares of Royalty Pharma worth $1.56B as of Q2 2026.
  • BlackRock bought 1,925,232 Royalty Pharma shares in Q2 2026, an estimated $100M.
  • Royalty Pharma made up 0.02% of BlackRock's portfolio in Q2 2026, its #531 holding.
  • BlackRock first reported a position in Royalty Pharma in Q2 2020 and has held it in 25 quarters since.
  • 643 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.